ABBVAbbVieFinished
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 20 (final count)
- Started
- Nov 8, 2021
- Main results expected
- Oct 9, 2025
- Fully finished
- Oct 9, 2025
- Results posted
- Oct 21, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)
Measured over: Up to 46 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05105841 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC